Breaking Finance News

ValuEngine downgraded Neurometrix Inc (NASDAQ:NURO) to Strong Sell in a report released today.

ValuEngine has downgraded Neurometrix Inc (NASDAQ:NURO) to Strong Sell in a report released on 6/02/2017.

Yesterday Neurometrix Inc (NASDAQ:NURO) traded -0.58% lower at $3.69. The company’s 50-day moving average is $1.99 and its 200-day moving average is $2.08. The last stock close price is up -17.73% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time. 35,210 shares of the stock were exchanged, down from an average trading volume of 62,185

See Chart Below

Neurometrix Inc (NASDAQ:NURO)

Neurometrix Inc has a 52 week low of $1.60 and a 52 week high of $11.60 The company’s market cap is currently $0.

In addition to ValuEngine reporting its target price, a total of 2 firms have issued a report on the stock. The consensus target price is $4.75 with 0 firms rating the stock a strong buy, 1 firm rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

General Information About Neurometrix Inc (NASDAQ:NURO)

NeuroMetrix, Inc. is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. Its products include ADVANCE NCS/EMG System (the ADVANCE System), Quell, SENSUS and DPNCheck. Quell is a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems. The SENSUS pain therapy device, the technological predecessor to Quell, is a prescription neuro-stimulation device based on transcutaneous electrical nerve stimulation (TENS) for relief of chronic, intractable pain. DPNCheck is a quantitative nerve conduction test. ADVANCE System is a platform for the performance of traditional nerve conduction studies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.